Drug Discovery World

NOVEMBER 28, 2023

The peer-reviewed article titled ‘Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease (PD) mouse model’ was the result of collaborative work between Cambridge University, Harvard Medical School, and Mission Therapeutics.

In-Vivo 52

In-Vivo Protein Drugs Research 52

Delveinsight

FEBRUARY 25, 2021

Cambridge, Massachusetts-based Beam aims to make more precise edits with genetic medicines, which employ base-editing. A new study from UCLA and Stanford University researchers observes that three-dimensional human stem cell-derived brain organoids can mature in a strikingly similar way to human brain development.

DNA 52

DNA In-Vivo Genetics Medicine 52

Drug Discovery World

NOVEMBER 9, 2023

Thereafter, there will be two presentations, which are: Jan Terje Andersen, PhD, Professor, Department of Pharmacology, University of Oslo; Research Group Leader, Department of Immunology, Oslo University Hospital, on: ‘Biology-based engineering of versatile antibody and albumin technologies’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 13, 2023

PLM and generative modelling for de novo degisn This session will begin with chairperson’s remarks from Victor Greiff, PhD, Associate Professor, Immunology, University of Oslo. He will discuss selection technologies for membrane targets using advances in whole cell panning and comparative deep sequencing.

Protein 59

Protein Antibody Engineer Scientist 59

XTalks

FEBRUARY 11, 2021

Franklin studied physical chemistry at Newnham College, University of Cambridge, graduating in 1941. She then set off to Cambridge with a fellowship she received to do research in physical chemistry. She was actually able to use the research for her doctoral thesis, graduating with a doctorate from Cambridge in 1945.

Genetics 119

Genetics DNA Genome Genomics 119